CA2922013C - Inducteurs chimiques d'hemoglobine foetale - Google Patents
Inducteurs chimiques d'hemoglobine foetale Download PDFInfo
- Publication number
- CA2922013C CA2922013C CA2922013A CA2922013A CA2922013C CA 2922013 C CA2922013 C CA 2922013C CA 2922013 A CA2922013 A CA 2922013A CA 2922013 A CA2922013 A CA 2922013A CA 2922013 C CA2922013 C CA 2922013C
- Authority
- CA
- Canada
- Prior art keywords
- hbf
- thalassemia
- blood
- beta
- globin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne de manière générale des compositions contenant des composés chimiques et des compositions et des formulations pharmaceutiques des composés qui augmentent l'hémoglobine totale ou la protéine globine, telle que la globine embryonnaire ou ftale, ou la prolifération de cellules exprimant l'hémoglobine. Des composés préférés comprennent le bensérazide, un inhibiteur de l'histone désacétylase à base de benzamide, tel que l'entinostat ou un ou plusieurs parmi l'ambroxol, la desloratadine, le resvératrol ou le NSC-95397. Ces compositions peuvent être utilisées pour traiter ou prévenir les symptômes associés à des drépanocytoses, des thalassémies bêta et d'autres déficiences des cellules sanguines et troubles sanguins. L'invention concerne également des procédés d'administration de ces compositions à des sujets et d'utilisation comme aide médicale pour le traitement et la prévention d'anémies provoquées par des mutations du gène de la globine et d'autres troubles de des globules rouges.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3120111A CA3120111A1 (fr) | 2013-08-20 | 2014-08-20 | Inducteurs chimiques d'hemoglobine foetale |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361867965P | 2013-08-20 | 2013-08-20 | |
US61/867,965 | 2013-08-20 | ||
PCT/US2014/051887 WO2015026939A1 (fr) | 2013-08-20 | 2014-08-20 | Inducteurs chimiques d'hémoglobine foetale |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3120111A Division CA3120111A1 (fr) | 2013-08-20 | 2014-08-20 | Inducteurs chimiques d'hemoglobine foetale |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2922013A1 CA2922013A1 (fr) | 2015-02-26 |
CA2922013C true CA2922013C (fr) | 2021-06-08 |
Family
ID=52484128
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3120111A Pending CA3120111A1 (fr) | 2013-08-20 | 2014-08-20 | Inducteurs chimiques d'hemoglobine foetale |
CA2922013A Active CA2922013C (fr) | 2013-08-20 | 2014-08-20 | Inducteurs chimiques d'hemoglobine foetale |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3120111A Pending CA3120111A1 (fr) | 2013-08-20 | 2014-08-20 | Inducteurs chimiques d'hemoglobine foetale |
Country Status (2)
Country | Link |
---|---|
CA (2) | CA3120111A1 (fr) |
WO (1) | WO2015026939A1 (fr) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009536659A (ja) * | 2006-05-09 | 2009-10-15 | ヘマクエスト・ファーマシューティカルズ,インコーポレーテッド | 血液疾患の治療法 |
WO2008088331A1 (fr) * | 2007-01-19 | 2008-07-24 | Gloucester Pharmaceuticals | Methodes permettant d'augmenter le taux d'hemoglobine fœtale humaine |
-
2014
- 2014-08-20 WO PCT/US2014/051887 patent/WO2015026939A1/fr active Application Filing
- 2014-08-20 CA CA3120111A patent/CA3120111A1/fr active Pending
- 2014-08-20 CA CA2922013A patent/CA2922013C/fr active Active
Also Published As
Publication number | Publication date |
---|---|
WO2015026939A1 (fr) | 2015-02-26 |
CA3120111A1 (fr) | 2015-02-26 |
CA2922013A1 (fr) | 2015-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9675595B2 (en) | Synergistic combinations of PI3K- and MEK-inhibitors | |
WO2012031125A2 (fr) | Inversion des effets d'une anesthésie générale par administration de phénidate de méthyle, d'amphétamine, de modafinil, d'amantadine, et/ou de caféine | |
AU2021200321A1 (en) | ADO-Resistant Cysteamine Analogs And Uses Thereof | |
CN108472275A (zh) | 治疗缺血性中风的组合物及方法 | |
WO2012142413A2 (fr) | Compositions à base de nitrite et leurs utilisations | |
CA2928442A1 (fr) | Utilisation de la cysteamine et de ses derives pour traiter des maladies mitochondriales | |
CN109417016B (zh) | 用于治疗缺血-再灌注损伤的戊二酸化合物 | |
US9018176B2 (en) | Inducers of hematopoiesis and fetal globin production for treatment of cytopenias and hemoglobin disorders | |
US20160128954A1 (en) | Methods of Treating Huntington's Disease Using Cysteamine Compositions | |
US10111846B2 (en) | S isomers of alpha-methyl-hydrocinnamic acid for the treatment of blood disorders | |
CA2922013C (fr) | Inducteurs chimiques d'hemoglobine foetale | |
CA3218585A1 (fr) | Composition pour le traitement d'etats pathologiques auto-immuns, allo-immuns, inflammatoires et mitochondriaux, et leurs utilisations | |
WO2007037258A1 (fr) | Agent thérapeutique destiné au trouble déficitaire de l’attention avec hyperactivité | |
KR101436644B1 (ko) | 당뇨병 치료제 | |
RU2538666C2 (ru) | Препарат для нормализации процессов перекисного окисления липидов у животных | |
US20070179194A1 (en) | Method for the treatment of diabetes | |
TW201731506A (zh) | 糖尿病治療劑之倂用 | |
TW202421123A (zh) | Hdac抑制劑oki-179用於治療由mapk路徑突變引起之癌症 | |
EP3441070A1 (fr) | Médicament pour prévenir ou traiter l'acidose lactique | |
Class et al. | Patent application title: INDUCERS OF HEMATOPOIESIS AND FETAL GLOBIN PRODUCTION FOR TREATMENT OF CYTOPENIAS AND HEMOGLOBIN DISORDERS Inventors: Susan Perrine (Weston, MA, US) Douglas V. Faller (Weston, MA, US) Douglas V. Faller (Weston, MA, US) Assignees: TRUSTEES OF BOSTON UNIVERSITY | |
WO2024026509A2 (fr) | Sélection de thérapie et traitement de troubles neurodégénératifs | |
JP2016533323A (ja) | 多発性硬化症の治療のためのラキニモド併用療法 | |
AU2014346703A1 (en) | Use of cysteamine and derivatives thereof to treat mitochondrial diseases | |
WO2007117398A2 (fr) | Compositions outils oncologiques et procédés d'utilisation pour détecter et traiter des tumeurs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20160219 |